SONOSCAPE(SZ:300633) Shang Hai Zheng Quan Bao·2025-10-17 19:18Summary of the Incentive Plan Announcement Core Viewpoint The announcement details the implementation of the 2025 Restricted Stock and Stock Option Incentive Plan by Shenzhen Kaili Biomedical Technology Co., Ltd., which includes the granting of restricted stocks and stock options to 405 incentive objects, aimed at motivating key personnel and enhancing company performance. Group 1: Incentive Plan Overview - The company has approved the granting of 1.914 million shares of restricted stock and 3.9678 million stock options to 405 incentive objects, including directors, senior management, and key technical personnel [1][21]. - The grant date for the restricted stock and stock options is set for October 16, 2025, with a grant price of 15.93 yuan per share for restricted stock and an exercise price of 31.86 yuan per option [2][17]. Group 2: Performance Assessment Requirements - The performance assessment for the incentive plan will be conducted annually from 2025 to 2028, with specific targets set for each fiscal year [5][6]. - If the company fails to meet the performance targets in any given year, the corresponding restricted stocks and stock options for that year will not vest or be exercisable, and will be forfeited [6][10]. Group 3: Decision-Making Process - The plan underwent a thorough decision-making process, including multiple board meetings and approvals from the remuneration and assessment committee, ensuring compliance with relevant laws and regulations [11][13][22]. - The company conducted a self-examination regarding insider trading by participants in the incentive plan, confirming no violations occurred in the six months prior to the grant date [24]. Group 4: Financial Implications - The funds raised through this incentive plan will be used to supplement the company's working capital [25]. - The company anticipates that the costs associated with the incentive plan will have a minor impact on net profits, while the potential positive effects on performance and management motivation are expected to outweigh these costs [30].